Eli Lilly has partnered with Lila Bio, a pioneer in AI-enabled protein design, to co-develop radioligand therapies targeting solid tumors. Using Lila’s AI and machine learning platforms, the collaboration aims to discover novel receptor targets and engineer highly specific binding molecules for improved imaging and treatment. Radioligand therapy permits selective delivery of radioactive isotopes to cancer cells, minimizing damage to healthy tissue. This initiative harnesses computational design to overcome traditional hurdles in binder development.